EA201500609A1 - Твёрдая дисперсия селективного модулятора рецептора прогестерона - Google Patents

Твёрдая дисперсия селективного модулятора рецептора прогестерона

Info

Publication number
EA201500609A1
EA201500609A1 EA201500609A EA201500609A EA201500609A1 EA 201500609 A1 EA201500609 A1 EA 201500609A1 EA 201500609 A EA201500609 A EA 201500609A EA 201500609 A EA201500609 A EA 201500609A EA 201500609 A1 EA201500609 A1 EA 201500609A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solid dispersion
progesterone receptor
receptor modulator
selective progesterone
selective
Prior art date
Application number
EA201500609A
Other languages
English (en)
Other versions
EA029701B1 (ru
Inventor
Флориан Баттюн
Пьер-Ив Жувен
Жером Эк
Оде Колен
Original Assignee
Лаборатуар Хра-Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47878221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201500609(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лаборатуар Хра-Фарма filed Critical Лаборатуар Хра-Фарма
Publication of EA201500609A1 publication Critical patent/EA201500609A1/ru
Publication of EA029701B1 publication Critical patent/EA029701B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)

Abstract

Объектом настоящего изобретения является твёрдая дисперсия, содержащая активное начало, выбранное из группы, содержащей селективные модуляторы рецептора прогестерона, их метаболиты и их смеси, и фармацевтически приемлемое полимерное вспомогательное вещество. Также, объектом изобретения являются фармацевтическая композиция, содержащая твёрдую дисперсию, и её применение в терапевтических целях.
EA201500609A 2012-12-06 2013-12-05 Твёрдая дисперсия селективного модулятора рецептора прогестерона, способы ее получения и композиции на ее основе EA029701B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1261721A FR2999081B1 (fr) 2012-12-06 2012-12-06 Dispersion solide d'un modulateur selectif du recepteur a la progesterone
PCT/FR2013/052952 WO2014087106A1 (fr) 2012-12-06 2013-12-05 Dispersion solide d'un modulateur selectif du recepteur a la progesterone

Publications (2)

Publication Number Publication Date
EA201500609A1 true EA201500609A1 (ru) 2015-09-30
EA029701B1 EA029701B1 (ru) 2018-05-31

Family

ID=47878221

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500609A EA029701B1 (ru) 2012-12-06 2013-12-05 Твёрдая дисперсия селективного модулятора рецептора прогестерона, способы ее получения и композиции на ее основе

Country Status (19)

Country Link
US (1) US20160213684A1 (ru)
EP (1) EP2928499B1 (ru)
JP (1) JP2016506390A (ru)
CN (1) CN105120899B (ru)
BR (1) BR112015013110B1 (ru)
CL (1) CL2015001559A1 (ru)
CR (1) CR20150299A (ru)
DO (1) DOP2015000137A (ru)
EA (1) EA029701B1 (ru)
EC (1) ECSP15022501A (ru)
ES (1) ES2666618T3 (ru)
FR (1) FR2999081B1 (ru)
GE (1) GEP201706740B (ru)
MD (1) MD4591C1 (ru)
MX (1) MX362151B (ru)
NI (1) NI201500076A (ru)
PE (1) PE20151783A1 (ru)
UA (1) UA115796C2 (ru)
WO (1) WO2014087106A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
CN108186586B (zh) * 2018-03-01 2020-12-29 常州市第四制药厂有限公司 一种烯丙雌醇片剂及其制备方法
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
CN111714444B (zh) * 2020-06-23 2022-12-20 南京海纳医药科技股份有限公司 一种醋酸乌利司他口服固体制剂及其制备方法
CN113406230A (zh) * 2021-06-17 2021-09-17 河南泰丰生物科技有限公司 一种醋酸乌利司他固体制剂溶出曲线的测定方法
WO2023033900A1 (en) * 2021-09-06 2023-03-09 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
JPH10505574A (ja) * 1994-07-26 1998-06-02 ラボラトワール エフィク 乾燥製剤の製造方法と、この方法で得られる医薬組成物
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
WO2003055524A1 (en) * 2001-12-21 2003-07-10 Pantarhei Bioscience B.V. Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US8865200B2 (en) 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
MX2009006912A (es) * 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
CN102395373A (zh) 2009-04-14 2012-03-28 Hra医药实验室 按需避孕方法
CN102107007B (zh) * 2011-01-28 2012-11-07 广州朗圣药业有限公司 甾体类抗孕激素组合物及其制备方法
CN102600001A (zh) * 2011-01-19 2012-07-25 国家人口计生委科学技术研究所 缓释米非司酮阴道环制剂及其应用

Also Published As

Publication number Publication date
ECSP15022501A (es) 2016-01-29
CN105120899B (zh) 2018-07-24
MD20150060A2 (ru) 2015-10-31
BR112015013110B1 (pt) 2020-07-14
DOP2015000137A (es) 2015-08-31
UA115796C2 (uk) 2017-12-26
CL2015001559A1 (es) 2016-01-04
MD4591C1 (ru) 2019-04-30
MD4591B1 (ru) 2018-09-30
NI201500076A (es) 2015-11-13
MX362151B (es) 2018-12-24
CN105120899A (zh) 2015-12-02
CR20150299A (es) 2015-08-14
FR2999081A1 (fr) 2014-06-13
BR112015013110A2 (pt) 2017-07-11
WO2014087106A1 (fr) 2014-06-12
EP2928499B1 (fr) 2018-01-31
US20160213684A1 (en) 2016-07-28
EP2928499A1 (fr) 2015-10-14
GEP201706740B (en) 2017-09-25
ES2666618T3 (es) 2018-05-07
EA029701B1 (ru) 2018-05-31
MX2015007127A (es) 2016-04-11
PE20151783A1 (es) 2015-12-20
JP2016506390A (ja) 2016-03-03
FR2999081B1 (fr) 2015-02-27

Similar Documents

Publication Publication Date Title
EA201500609A1 (ru) Твёрдая дисперсия селективного модулятора рецептора прогестерона
CY1121675T1 (el) Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
CL2011000570A1 (es) Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras.
JOP20190183B1 (ar) معدِلات مستقبلات الاستروجين
CY1118884T1 (el) Προϊον συν-μικρονισμου που περιλαμβανει εκλεκτικο ρυθμιστη υποδοχεα προγεστερονης
EA201400444A1 (ru) Производные 2-оксопиперидинила
EA201991734A1 (ru) Модуляторы рецептора эстрогена
TH1401006422A (th) ตัวควบคุม ออร์แฟน รีเซฟเตอร์ ชนิดสัมพันธ์กับเรตินอยด์แกมมา (RORY) ชนิดใหม่ (novel retinoid-related orphan receptor gamma modulators), กระบวนการสำหรับการเตรียมของสิ่งนั้น, องค์ประกอบทางเภสัชกรรมที่บรรจุตัวควบคุมเหล่านี้ และการใช้ของสิ่งนั้น

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU